RADNOR,
Pa., Nov. 27, 2023 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a clinical-stage biopharmaceutical company, today
announced that Dr. Jonathan Javitt,
Founder and Chief Scientist of NRx Pharmaceuticals, will present a
corporate overview at the Noble Capital Markets' 19th Annual
Emerging Growth Investor Conference on Monday, December 4th, 2023, at the College of
Business Executive Education Building at Florida Atlantic University in Boca Raton, Fla.
Management will conduct in-person one-on-one meetings throughout
the conference and deliver the Company's presentation as shown
below.
Noble Capital Markets' 19th Annual Emerging
Growth Equity Conference
When: Monday, December
4th, 2023
Time: 4:30-4:55 PM
– Presentation Room 1
College of Business Executive Education Building
at Florida Atlantic University in
Boca Raton, Florida
An archived replay will be available on the Company's website
after the event at https://ir.nrxpharma.com/events. The replay
will be available for 90 days after the event.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx has partnered with Alvogen Pharmaceuticals around
the development and marketing of NRX-101 for the treatment of
suicidal bipolar depression. NRX-101 additionally has potential to
act as a non-opioid treatment for chronic pain.
NRx has recently announced plans to submit a New Drug Application
for ketamine in the treatment of suicidal depression, based on
results of well-controlled clinical trials conducted under the
auspices of the US National Institutes of Health and newly obtained
data from French health authorities, licensed under a data sharing
agreement. NRx was awarded Fast Track Designation for development
of ketamine (NRX-100) by the US FDA as part of a protocol to treat
patients with acute suicidality.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-present-at-noble-capital-markets-19th-annual-emerging-growth-investor-conference-301998363.html
SOURCE NRx Pharmaceuticals, Inc.